MA34144B1 - Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide - Google Patents

Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide

Info

Publication number
MA34144B1
MA34144B1 MA35288A MA35288A MA34144B1 MA 34144 B1 MA34144 B1 MA 34144B1 MA 35288 A MA35288 A MA 35288A MA 35288 A MA35288 A MA 35288A MA 34144 B1 MA34144 B1 MA 34144B1
Authority
MA
Morocco
Prior art keywords
tetrahydroisoquinoline
cyclohexylmethyl
sulfonamide
ethyl
preparation
Prior art date
Application number
MA35288A
Other languages
English (en)
Inventor
Steven Elenbaas
Robert Allan Farr
John Michael Kane
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34144(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34144B1 publication Critical patent/MA34144B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'INVENTION CONCERNE UN PROCÉDÉ INDUSTRIELLEMENT APPLICABLE POUR LA PRÉPARATION DU 2-(CYCLOHEXYLMÉTHYL)-N-{2-[(2S)-1-MÉTHYLPYRROLIDIN-2-YL]ÉTHYL}-1,2,3,4- TÉTRAHYDROISOQUINOLÉINE-7-SULFONAMIDE ET DE SES SELS.
MA35288A 2010-03-05 2011-03-04 Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide MA34144B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
FR1059750 2010-11-25
PCT/US2011/027131 WO2011109680A2 (fr) 2010-03-05 2011-03-04 Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide

Publications (1)

Publication Number Publication Date
MA34144B1 true MA34144B1 (fr) 2013-04-03

Family

ID=44012569

Family Applications (2)

Application Number Title Priority Date Filing Date
MA35286A MA34142B1 (fr) 2010-03-05 2011-03-04 Procede pour la preparation du 2-(cyclohexylmethyl)-1-methylpyrrolidin-2-yl)ethyl)-1,2,3,4-tetrahydroisoquinoleine-7-sulfonamide
MA35288A MA34144B1 (fr) 2010-03-05 2011-03-04 Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA35286A MA34142B1 (fr) 2010-03-05 2011-03-04 Procede pour la preparation du 2-(cyclohexylmethyl)-1-methylpyrrolidin-2-yl)ethyl)-1,2,3,4-tetrahydroisoquinoleine-7-sulfonamide

Country Status (27)

Country Link
US (2) US8748615B2 (fr)
EP (2) EP2542530A2 (fr)
JP (2) JP2013521308A (fr)
KR (2) KR20130047685A (fr)
CN (2) CN103068815A (fr)
AR (2) AR080375A1 (fr)
AU (2) AU2011223560A1 (fr)
BR (2) BR112012022356A2 (fr)
CA (2) CA2789669A1 (fr)
CL (2) CL2012002451A1 (fr)
CO (2) CO6630129A2 (fr)
CR (1) CR20120467A (fr)
DO (1) DOP2012000228A (fr)
EC (1) ECSP12012207A (fr)
GT (1) GT201200228A (fr)
IL (2) IL221341A (fr)
MA (2) MA34142B1 (fr)
MX (2) MX2012009413A (fr)
NZ (2) NZ601498A (fr)
PE (1) PE20130007A1 (fr)
RU (2) RU2012142338A (fr)
SG (2) SG183256A1 (fr)
TN (1) TN2012000361A1 (fr)
TW (2) TW201144284A (fr)
UY (2) UY33262A (fr)
WO (2) WO2011109680A2 (fr)
ZA (1) ZA201205311B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
CN102816101A (zh) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
EP1070714B1 (fr) 1998-04-10 2004-08-04 Japan Tobacco Inc. Composes d'amidine
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CA2347095A1 (fr) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant
EP1185275A1 (fr) 1999-04-01 2002-03-13 Pfizer Products Inc. Aminopyrimidines comme inhibiteurs de sorbitol deshydrogenase
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
PL356769A1 (en) 1999-12-03 2004-07-12 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
MXPA03003397A (es) 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
ES2251514T3 (es) * 2000-10-30 2006-05-01 Warner-Lambert Company Llc Ligandos del receptor serotonina de aminoalquilpirrolidina y composiciones, sus usos farmaceuticos y metodos para su sintesis.
WO2002076925A2 (fr) 2001-03-23 2002-10-03 Eli Lilly And Company Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
WO2002102770A1 (fr) * 2001-06-18 2002-12-27 Maruha Corporation Nouveau compose aliphatique, technique de synthese et technique d'utilisation
US20050043304A1 (en) 2001-08-01 2005-02-24 Yutaka Kato Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1461311A2 (fr) 2001-12-26 2004-09-29 Bayer HealthCare AG Derives d'uree antagonistes du vr-1
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
CA2521625A1 (fr) 2003-04-17 2004-11-04 Merck & Co., Inc. Modulateurs tetrahydroisoquinoline et tetrahydropyridopyridine cyclopentyles heterocycliques de l'activite des recepteurs de chimiokine
FR2857695B1 (fr) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne
WO2005067502A2 (fr) 2004-01-02 2005-07-28 Merck & Co., Inc. Modulateurs d'amide cyclopentyle d'alkylamino, arylamino et sulfonamido de l'activite des recepteurs de la chimiokine
JP2007518799A (ja) 2004-01-20 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性モジュレーターとしての２，６−二置換ピペリジン
CN1972913A (zh) 2004-04-26 2007-05-30 默克公司 四氢吡喃基环戊基四氢吡啶并吡啶趋化因子受体活性调节剂
WO2005110409A2 (fr) 2004-04-26 2005-11-24 Merck & Co., Inc. Modulateurs tetrahydropyranyle cyclopentyle de tetrahydroisoquinoline 1 substituee et 1,1-disubstituee de l'activite des recepteurs de chimiokine
AU2005247361B2 (en) 2004-05-11 2011-03-17 Incyte Corporation 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1630159A1 (fr) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Antagonistes des recepteurs 5-HT7
EP1630158A1 (fr) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Antagonistes des recepteurs 5-HT7
EP1809624B1 (fr) 2004-08-28 2013-11-20 AstraZeneca AB Dérivés de pyrimidinesulfonamide en tant que modulateurs du récepteur de chimiokine
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
EP1828185B1 (fr) 2004-12-21 2009-05-06 SmithKline Beecham Corporation Inhibiteurs de la kinase erbb a base de 2-pyrimidinyle pyrazolopyridine
WO2006067587A2 (fr) 2004-12-22 2006-06-29 Pfizer Limited Composes chimiques
EP1844045B1 (fr) 2005-01-26 2009-11-04 F.Hoffmann-La Roche Ag Derives methanone phenyliques et leur utilisation en tant qu'inhibiteurs du transporteur 1 de la glycine
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
CA2607670A1 (fr) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Derives bicycliques utilises en tant que modulateurs de canaux ioniques
EP1911747A1 (fr) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Dérivés de pyrazoline substitués par un groupe sulfonamide, leur préparation et leur utlisation comme des modulateurs de CB1
JP5443975B2 (ja) 2007-04-27 2014-03-19 富山化学工業株式会社 新規なスルホンアミド誘導体またはその塩
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
WO2010127272A2 (fr) 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Dérivés hydroxyéthylamino sulfonamides
PL2445899T3 (pl) 2009-06-26 2017-08-31 Sanofi Nowe sole fumaranowe antagonisty receptora histaminy H3
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida

Also Published As

Publication number Publication date
IL221341A (en) 2014-05-28
TW201144285A (en) 2011-12-16
CA2787427C (fr) 2017-10-10
KR20130047685A (ko) 2013-05-08
IL221339A0 (en) 2012-10-31
MX2012009413A (es) 2012-09-07
MX2012008422A (es) 2012-08-15
ZA201205311B (en) 2013-03-27
ECSP12012207A (es) 2013-03-28
KR20130038186A (ko) 2013-04-17
KR101783679B1 (ko) 2017-10-10
EP2542530A2 (fr) 2013-01-09
IL221341A0 (en) 2012-10-31
AU2011222588B2 (en) 2016-09-08
CL2012002451A1 (es) 2012-11-30
CO6630129A2 (es) 2013-03-01
AU2011222588A1 (en) 2012-08-23
US20130123302A1 (en) 2013-05-16
SG182576A1 (en) 2012-08-30
CN103221394A (zh) 2013-07-24
AU2011223560A1 (en) 2012-09-13
CL2012002452A1 (es) 2012-11-30
AR080375A1 (es) 2012-04-04
BR112012022356A2 (pt) 2016-08-30
WO2011109675A3 (fr) 2012-11-22
GT201200228A (es) 2013-11-21
RU2012142310A (ru) 2014-04-10
TW201144284A (en) 2011-12-16
NZ601498A (en) 2014-12-24
TN2012000361A1 (en) 2014-01-30
WO2011109675A2 (fr) 2011-09-09
CA2787427A1 (fr) 2011-09-09
CA2789669A1 (fr) 2011-09-09
JP2013521308A (ja) 2013-06-10
CN103068815A (zh) 2013-04-24
NZ602009A (en) 2015-01-30
SG183256A1 (en) 2012-09-27
UY33263A (es) 2011-09-30
US8779145B2 (en) 2014-07-15
BR112012022234A2 (pt) 2015-12-15
UY33262A (es) 2011-09-30
EP2556064B1 (fr) 2014-10-15
JP5927126B2 (ja) 2016-05-25
WO2011109680A2 (fr) 2011-09-09
US8748615B2 (en) 2014-06-10
EP2556064A2 (fr) 2013-02-13
PE20130007A1 (es) 2013-02-01
MA34142B1 (fr) 2013-04-03
WO2011109680A3 (fr) 2012-12-20
US20130137718A1 (en) 2013-05-30
CR20120467A (es) 2012-10-05
AR080374A1 (es) 2012-04-04
CO6630099A2 (es) 2013-03-01
DOP2012000228A (es) 2013-01-15
JP2013521309A (ja) 2013-06-10
RU2012142338A (ru) 2014-04-10

Similar Documents

Publication Publication Date Title
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
FR2929271B1 (fr) Procede pour la preparation du 1,2,3,3,3-pentafluoropropene- 1
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
EA201200741A1 (ru) Способ получения этексилата дабигатрана
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201290416A1 (ru) Новые спиропиперидиновые соединения
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
IN2012DN01273A (fr)
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MA34144B1 (fr) Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide
TN2011000620A1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
EA201300440A1 (ru) Способ получения (3s,3s') 4,4'-дисульфандиилбис(3-аминобутан-1-сульфокислоты)
FR2927900B1 (fr) Procede de preparation d'alpha-aminoacetals optiquement actifs.
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения
MY183201A (en) Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
MX354020B (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer.
MX2014001409A (es) Metodo para tratar esquizofrenia.
NI201200127A (es) Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida.
UA106380C2 (ru) Фумаратные соли антагониста гистаминового рецептора н3
MA50151B1 (fr) Procedé pour la préparation des enantiomères de pirlindole et leurs sels
LV14037A (lv) Ftalimidoamlodipīna iegūšanas metode
UA52319U (ru) Способ интраоперационного определения дистальной границы процесса при хирургическом лечении переднего медиастинита
LV14036A (lv) Trīs komponentu metode ftalimidoamlodipīna iegūšanai jonu šķidrumu promotētās reakcijās
LV14038A (lv) Viena reaktora metode ftalimidoamlodipīna iegūšanai jonu šķidrumu promotētās reakcijās